Use HOPE-3 To Justify Statin Use For Primary Prevention in Non-Whites

You'll see more patients on statins for PRIMARY prevention.

We know statins improve outcomes for SECONDARY prevention. But evidence has been murkier in other patients...especially nonwhites.

Now the HOPE-3 study will provide more clarity for primary prevention patients with a 10-year CV risk of about 7.5% or higher.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Not sold to individuals